UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia
Some 330 permanent jobs are expected to be based at the approximately 460,000-square-foot campus, which will occupy 79 acres within the Rowen innovation district in Georgia’s Gwinnett County. The post UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia appeared first on GEN - Genetic Engineering and Biotechnology News .
UCB, a Belgian drug developer, has dedicated its first U.S. manufacturing campus for biologics in Rowen, Georgia. The $2 billion campus, set to open by 2032 or 2033, will support commercial production of recent and future biologic medicines. It will employ 330 people full-time and utilize advanced technologies like AI, automation, and advanced manufacturing.
Georgia's strong life sciences ecosystem, skilled workforce, infrastructure, and access to academic institutions were key factors in the decision. Georgia has committed $174 million in incentives and infrastructure investments to support UCB's project, positioning the state as a manufacturing hub in the Southeast. UCB CEO Jean-Christophe Tellier emphasized the company's long-term commitment to patients, scientific innovation, and economic growth.
The campus, occupying 79 acres in the Rowen innovation district of Gwinnett County, will be built on 460,000 square feet of land purchased from the Rowen Foundation. The dedication ceremony featured dignitaries from the United States, Belgium, and Georgia, including Georgia Gov. Brian Kemp, U.S. Department of Commerce Under Secretary for Industry and Security Jeffrey Kessler, and UCB CEO Jean-Christophe Tellier.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
